| Literature DB >> 35159936 |
Piotr Desperak1, Aneta Desperak1, Bożena Szyguła-Jurkiewicz1, Piotr Rozentryt1,2, Andrzej Lekston1, Mariusz Gąsior1.
Abstract
BACKGROUND: The aim of this study was to determine the influence of acute exposure to air pollutants on patients' profile, short- and mid-term outcomes of hospitalized patients with coronary artery disease (CAD) treated with coronary angioplasty.Entities:
Keywords: acute coronary syndromes; air pollutions; chronic coronary syndromes; percutaneous coronary intervention
Year: 2022 PMID: 35159936 PMCID: PMC8836379 DOI: 10.3390/jcm11030484
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Clinical characteristics of total sample and study groups.
| Factor | Total | CCS | ACS | ||||
|---|---|---|---|---|---|---|---|
| AP ≤ Q3 | AP > Q3 |
| AP ≤ Q3 | AP > Q3 |
| ||
| Age, years; median (Q1–Q3) | 65 (58–73) | 65 (59–73) | 66 (59–73) | 0.69 | 64 (57–73) | 65 (57–73) | 0.70 |
| BMI, kg/m2; median (Q1–Q3) | 28.1 (25.4–31.2) | 28.1 (25.5–31.1) | 28.1 (25.4–31.2) | 0.81 | 27.8 (25.3–31.2) | 28.1 (25.4–31.2) | 0.29 |
| Female, % | 31.1 | 32.1 | 29.2 | 0.07 | 32.3 | 31.9 | 0,67 |
| Prior MI, % | 37.4 | 45.3 | 47.4 | 0.24 | 30.8 | 29.7 | 0.44 |
| Arterial hypertension, % | 75.0 | 82.9 | 81.1 | 0.19 | 68.4 | 70.5 | 0.15 |
| COPD, % | 6.1 | 6.2 | 6.5 | 0.66 | 6.3 | 5.3 | 0.31 |
| Atrial fibrillation, % | 12.6 | 13.0 | 15.0 | 0.11 | 12.6 | 10.4 | 0.034 |
| Diabetes mellitus, % | 34.8 | 38.6 | 38.6 | 0.98 | 31.6 | 31.9 | 0.83 |
| Dyslipidemia, % | 66.4 | 77.0 | 77.1 | 0.94 | 56.4 | 59.0 | 0.10 |
| PAD, % | 11.2 | 14.0 | 17.7 | 0.005 | 6.8 | 7.6 | 0.32 |
| Obesity, % | 28.8 | 29.1 | 29.9 | 0.64 | 27.5 | 28.0 | 0.80 |
| History of cigarette smoking, % | 46.7 | 49.6 | 48.9 | 0.68 | 43.8 | 45.2 | 0.39 |
| Stenocardial pain, % | 78.4 | 67.2 | 66.3 | 0.60 | 92.0 | 91.9 | 0.91 |
| SBP *, mmHg; median (Q1–Q3) | 135 (120–150) | 130 (120–140) | 130 (120–140) | 0.032 | 140 (130–163) | 140 (130–162) | 0.85 |
| DBP *, mmHg; median (Q1–Q3) | 80 (70–90) | 80 (70–85) | 80 (70–80) | 0.008 | 80 (72–92) | 80 (74–95) | 0.47 |
| HR *, mmHg; median (Q1–Q3) | 70 (65–80) | 70 (64–77) | 70 (64–80) | 0.41 | 75 (68–85) | 75 (67–85) | 0.25 |
| LVEF *, %; median (Q1–Q3) | 47 (40–52) | 50 (43–55) | 50 (40–55) | 0.28 | 45 (38–50) | 45 (38–50) | 0.46 |
| WBC *, thousand/mm3; | 8.2 (6.6–10.3) | 7.3 (6.1–8.8) | 7.2 (6.0–8.6) | 0.11 | 9.1 (7.4–11.9) | 9.3 (7.3–11.9) | 0.75 |
| HCT *, %; median (Q1–Q3) | 41.3 (38.3–43.8) | 41.2 (38.6–43.6) | 41.0 (38.2–43.4) | 0.16 | 41.3 (38.3–44.0) | 41.5 (38.1–44.1) | 0.45 |
| Hemoglobin *, mmol/L; | 8.7 (8.1–9.3) | 8.8 (8.1–9.3) | 8.7 (8.1–9.2) | 0.012 | 8.8 (8.1–9.4) | 8.8 (8.0–9.4) | 0.99 |
| Serum creatinine *, µmol/L; | 82.0 (69.5–98.8) | 80.5 (68.6–97.0) | 81.7 (69.5–98.0) | 0.16 | 83.4 (69.9–100.0) | 82.0 (69.7–100,0) | 0.39 |
| Glucose *, mmol/L; | 6.4 (5.5–8.3) | 5.8 (5.2–7.1) | 5.9 (5.2–7.3) | 0.52 | 7.0 (5.8–9.0) | 6.9 (5.8–9.1) | 0.99 |
| Multivessel CAD, % | 51.8 | 51.3 | 50.9 | 0.82 | 53.0 | 51.9 | 0.46 |
| Stent implantation, % | 88.7 | 89.9 | 89.5 | 0.73 | 88.8 | 87.3 | 0.14 |
| DES, % | 60.9 | 65.3 | 64.3 | 0.56 | 58.3 | 57.6 | 0.66 |
| In-hospital outcomes | |||||||
| Death, % | 2.2 | 1.1 | 0.6 | 0.15 | 3.5 | 3.2 | 0.60 |
| MI, % | 1.1 | 1.0 | 0.4 | 0.07 | 1.3 | 1.5 | 0.62 |
| Cardiac arrest, % | 3.5 | 1.4 | 0.8 | 0.09 | 5.3 | 5.6 | 0.63 |
| Pulmonary oedema, % | 2.5 | 0.1 | 0.1 | 0.66 | 4.9 | 4.0 | 0.16 |
| Cardiogenic shock, % | 2.5 | 0.1 | 0.1 | 0.65 | 4.9 | 4.1 | 0.26 |
| 30-day MACCE, % | 5.3 | 3.3 | 2.3 | 0.08 | 7.1 | 7.5 | 0.63 |
| Death, % | 2.8 | 1.0 | 1.0 | 0.98 | 4.1 | 4.4 | 0.71 |
| MI, % | 2.2 | 1.8 | 1.1 | 0.13 | 3.0 | 2.6 | 0.51 |
| ACS-driven PCI, % | 1.1 | 1.0 | 0.7 | 0.50 | 1.1 | 1.5 | 0.31 |
| Stroke, % | 0.1 | 0.1 | 0.0 | 0.84 | 0.1 | 0.2 | 0.67 |
| 12-month MACCE, % | 11.8 | 7.8 | 7.5 | 0.74 | 15.5 | 14.9 | 0.63 |
| Death, % | 5.4 | 2.9 | 3.3 | 0.52 | 7.2 | 7.2 | 0.96 |
| MI, % | 4.9 | 3.1 | 2.9 | 0.77 | 6.9 | 6.2 | 0.35 |
| ACS-driven PCI, % | 4.2 | 3.2 | 3.0 | 0.74 | 5.4 | 4.8 | 0.40 |
| Stroke, % | 0,7 | 0.7 | 0.6 | 0.66 | 0.5 | 0.9 | 0.12 |
* on admission; The subgroups AP > Q3—at least one of the air pollutants exceeds the third quartile. Abbreviations: ACS, acute coronary syndrome; AP, air pollutants; BMI, body mass index; CCS, chronic coronary syndrome; DBP, diastolic blood pressure; DES, drug-eluting stent; COPD, chronic obstructive pulmonary disease; HCT, hematocrit; HR, heart rate; LVEF, left ventricular ejection fraction; MACCE, major cardiac and cerebrovascular events; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; WBC, white blood cells.
Air pollutants during day of admission to the hospital in study groups.
| Factor | WHO | Study Population | CCS | ACS | |
|---|---|---|---|---|---|
| PM10, µg/m3; | 15 (20) | 36.2 (25.8–54.4) | 35.4 (25.8–53.4) | 36.8 (25.8–56.0) | 0.039 |
| SO2, µg/m3; | 40 (20) | 11.4 (7.5–19.5) | 10.9 (7.4–18.6) | 11.8 (7.6–20.2) | 0.0001 |
| NO, µg/m3; | 7.7 (4.2–16.2) | 7.8 (4.4–15.8) | 7.7 (4.0–16.4) | 0.17 | |
| NO2, µg/m3; | 25 (40) | 24.7 (18.5–32.2) | 24.6 (19.0–32.0) | 24.8 (18.2–32.5) | 0.51 |
| O3, µg/m3; | 100 (100) | 60.7 (37.0–84.7) | 62.7 (39.3–86.3) | 59.0 (35.3–83.7) | 0.0001 |
Abbreviations: NO, nitrogen monoxide; NO2, nitrogen dioxide; O3, daily maximum of 8-h mean of ozone; PM10, particulate matter with aerodynamic diameter < 10 µm; SO2, sulphur dioxide; WHO—World Health Organization.
The influence of exceeding 3rd quartiles of air pollutants on short- and mid-term outcomes in the chronic coronary syndromes (CCS; A) and acute coronary syndromes (ACS; B) subgroup. Abbreviations: BMI, body mass index; CAD, coronary artery disease; CCS, chronic coronary syndromes; EF, left ventricular ejection fraction; MACCE, major adverse cardiovascular or cerebrovascular events; MI, myocardial infarction; NO, nitric oxide; NO2, nitric dioxide; O3, ozone; PM10, particulate matter with aerodynamic diameter < 10 um; SBP, systolic blood pressure; SO2, sulfur dioxide; U-PCI, urgent percutaneous coronary intervention; WBC, white blood cells count.
|
|
| |||||||||
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
| |
| 30d MACCE | 1.15 | 0.73 | 1.54 | 0.33 | 1.48 | 0.32 | 1.05 | 0.91 | 0.46 | 0.17 |
| Covariates used in the model: | ||||||||||
| 30-day mortality | 1.31 | 0.56 | 1.26 | 0.66 | 0.85 | 0.75 | 1.14 | 0.76 | 0.83 | 0.68 |
| Covariates used in the model: | ||||||||||
| 30-day MI | 1.27 | 0.5 | 1.19 | 0.67 | 0.73 | 0.39 | 1.03 | 0.94 | 0.47 | 0.11 |
| Covariates used in the model: | ||||||||||
| 30-day stroke | - | - | - | - | - | - | - | - | - | - |
| not enough events to perform the multivariable analysis | ||||||||||
| 30-day ACS-driven PCI | 1.94 | 0.18 | 2.95 | 0.07 | 1.41 | 0.47 | 1.41 | 0.49 | 0.49 | 0.28 |
| Covariates used in the model: | ||||||||||
| 12-month MACCE | 0.88 | 0.63 | 1.25 | 0.44 | 1.06 | 0.83 | 1.22 | 0.41 | 0.76 | 0.34 |
| Covariates used in the model: | ||||||||||
| 12-month mortality | 1.58 | 0.2 | 2.29 | 0.043 | 0.99 | 0.98 | 1.37 | 0.34 | 0.82 | 0.59 |
| Covariates used in the model: | ||||||||||
| 12-month MI | 1.08 | 0.81 | 1.09 | 0.8 | 0.92 | 0.79 | 1.20 | 0.56 | 0.42 | 0.03086 |
| Covariates used in the model: | ||||||||||
| 12-month stroke | 0.41 | 0.18 | 1.26 | 0.71 | 0.51 | 0.23 | 0.75 | 0.6 | 1.54 | 0.36 |
| Covariates used in the model: | ||||||||||
| 12-month ACS-driven PCI | 1.07 | 0.71 | 0.90 | 0.66 | 1.23 | 0.28 | 1.02 | 0.91 | 0.93 | 0.75 |
| Covariates used in the model: | ||||||||||
|
|
| |||||||||
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
| |
| 30d MACCE | 1.97 | 0.0419 | 2.07 | 0.07 | 1.52 | 0.18 | 1.35 | 0.36 | 0.98 | 0.97 |
| Covariates used in the model: | ||||||||||
| 30-day mortality | 3.23 | 0.036 | 8.71 | 0.0017 | 1.33 | 0.58 | 2.34 | 0.11 | 1.13 | 0.84 |
| Covariates used in the model: | ||||||||||
| 30-day MI | 0.88 | 0.58 | 0.98 | 0.92 | 0.85 | 0.48 | 0.76 | 0.24 | 0.97 | 0.9 |
| Covariates used in the model: | ||||||||||
| 30-day stroke | - | - | - | - | - | - | - | - | - | - |
| not enough events to perform the multivariable analysis | ||||||||||
| 30-day ACS-driven PCI | 1.51 | 0.31 | 1.73 | 0.25 | 1.25 | 0.58 | 1.06 | 0.89 | 0.97 | 0.95 |
| Covariates used in the model: | ||||||||||
| 12-month MACCE | 1.14 | 0.48 | 1.11 | 0.62 ( | 1.06 | 0.74 | 0.87 | 0.47 | 1.24 | 0.27 |
| Covariates used in the model: | ||||||||||
| 12-month mortality | 1.12 | 0.67 | 1.11 | 0.72 | 0.90 | 0.69 | 1.12 | 0.67 | 0.88 | 0.65 |
| Covariates used in the model: | ||||||||||
| 12-month MI | 0.85 | 0.27 | 0.99 | 0.96 | 0.79 | 0.1 | 0.76 | 0.07 | 0.99 | 0.94 |
| Covariates used in the model: | ||||||||||
| 12-month stroke | 1.28 | 0.45 | 1.19 | 0.64 | 1.58 | 0.14 | 1.13 | 0.10 | 0.68 | 0.37 |
| Covariates used in the model: | ||||||||||
| 12-month ACS-driven PCI | 1.03 | 0.84 | 1.01 | 0.95 | 0.87 | 0.35 | 0.91 | 0.53 | 1.17 | 0.28 |
| Covariates used in the model: | ||||||||||